S. Gillessen 1 , * , A. Omlin 1 , G. Attard 2 , J. S. de Bono 2 , E. Efstathiou 3 , 4 , 5 , K. Fizazi 6 , S. Halabi 7 , P. S. Nelson 8 , O. Sartor 9 , M. R. Smith 10 , H. R. Soule 11 , H. Akaza 12 , T. M. Beer 13 , H. Beltran 14 , A. M. Chinnaiyan 15 , 16 , 17 , G. Daugaard 18 , I. D. Davis 19 , M. De Santis 20 , 21 , C. G. Drake 22 , R. A. Eeles 23 , S. Fanti 24 , M. E. Gleave 25 , A. Heidenreich 26 , M. Hussain 27 , N. D. James 20 , 28 , F. E. Lecouvet 29 , C. J. Logothetis 3 , 4 , K. Mastris 30 , S. Nilsson 31 , W. K. Oh 32 , D. Olmos 33 , 34 , 35 , A. R. Padhani 36 , C. Parker 37 , M. A. Rubin 38 , J. A. Schalken 39 , H. I. Scher 14 , 40 , A. Sella 41 , N. D. Shore 42 , E. J. Small 43 , C. N. Sternberg 44 , H. Suzuki 45 , C. J. Sweeney 46 , I. F. Tannock 47 , B. Tombal 48
03 June 2015
The first St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) Expert Panel identified and reviewed available evidence for the ten most important areas of controversy in advanced prostate cancer management. Recommendations based on expert opinion are presented. Detailed decisions on treatment will involve clinical consideration of disease extent and location, prior treatments, host factors, patient preferences and logistical and economic constraints.
The first St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) Expert Panel identified and reviewed the available evidence for the ten most important areas of controversy in advanced prostate cancer (APC) management. The successful registration of several drugs for castration-resistant prostate cancer and the recent studies of chemo-hormonal therapy in men with castration-naïve prostate cancer have led to considerable uncertainty as to the best treatment choices, sequence of treatment options and appropriate patient selection. Management recommendations based on expert opinion, and not based on a critical review of the available evidence, are presented. The various recommendations carried differing degrees of support, as reflected in the wording of the article text and in the detailed voting results recorded in supplementary Material, available at Annals of Oncology online . Detailed decisions on treatment as always will involve consideration of disease extent and location, prior treatments, host factors, patient preferences as well as logistical and economic constraints. Inclusion of men with APC in clinical trials should be encouraged.